Viyash Scientific Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Reflect Improved Price Appeal

Viyash Scientific’s price-to-earnings (P/E) ratio currently stands at 48.26, a figure that, while still elevated, is now considered fair relative to its historical expensive valuation status. This contrasts with several industry peers such as Gland Pharma and Emcure Pharma, which maintain expensive valuations with P/E ratios of 41.78 and 34.18 respectively. More strikingly, companies like Sai Life and Rubicon Research are classified as very expensive, with P/E ratios soaring above 80 and 100 respectively.

The company’s price-to-book value (P/BV) is 3.98, which aligns with a fair valuation stance, suggesting that the market is pricing the stock more reasonably relative to its net asset value. This is a significant improvement from prior assessments that labelled the stock as expensive, indicating that investors may now find the stock more attractive on a price basis.

Enterprise value to EBITDA (EV/EBITDA) at 16.59 further supports this view, positioning Viyash Scientific comfortably below some of its more richly valued peers such as Sai Life (47.23) and Wockhardt (41.61). This metric suggests that the company’s earnings before interest, taxes, depreciation and amortisation are being valued more conservatively, which could appeal to value-conscious investors.

Operational Efficiency and Returns

Viyash Scientific’s return on capital employed (ROCE) is 13.36%, indicating a decent level of operational efficiency and capital utilisation. While not outstanding, this figure is respectable within the Pharmaceuticals & Biotechnology sector, where capital intensity can vary widely. The return on equity (ROE) is more modest at 7.11%, signalling room for improvement in generating shareholder returns but still providing a foundation for growth.

These returns, combined with the valuation shift, suggest that the company is beginning to deliver on operational metrics that justify its current market price, especially when compared to peers with higher valuations but not necessarily superior returns.

Recent Market Performance and Price Movement

Despite the positive valuation shift, Viyash Scientific’s share price experienced a decline of 5.37% on the latest trading day, closing at ₹263.25 from a previous close of ₹278.20. The stock traded within a range of ₹259.30 to ₹271.35 during the session. Over the past week, the stock has declined by 3.20%, while the Sensex gained 0.73%, indicating some short-term pressure on the stock relative to the broader market.

However, longer-term returns paint a more encouraging picture. Year-to-date, Viyash Scientific has delivered a robust 26.47% return, significantly outperforming the Sensex’s negative 9.09% return over the same period. Over one year, the stock’s gain of 51.34% dwarfs the Sensex’s 4.10% decline, and over three years, the stock has surged 193.25%, compared to the Sensex’s 19.40% rise. Even over a decade, the stock has delivered a strong 130.23% return, underscoring its growth credentials despite recent volatility.

Comparative Valuation: Viyash Scientific vs Peers

When analysing Viyash Scientific’s valuation in the context of its peer group, it becomes clear that the stock’s fair valuation grade is a relative advantage. Many competitors in the Pharmaceuticals & Biotechnology sector are trading at very expensive multiples. For instance, Rubicon Research’s P/E ratio exceeds 104, while Sai Life and Wockhardt trade at P/E multiples of 84.18 and 76.57 respectively. These valuations imply heightened expectations for growth or profitability that may not be fully justified by fundamentals.

In contrast, Viyash Scientific’s PEG ratio of 1.14 suggests a reasonable balance between price, earnings, and growth expectations. This is notably higher than some peers like Gland Pharma (0.86) and Emcure Pharma (0.93), but still within a range that supports the recent upgrade to a Buy rating. The PEG ratio indicates that the stock’s price growth is more aligned with its earnings growth prospects, making it a more balanced investment proposition.

Mojo Score and Rating Upgrade

MarketsMOJO’s proprietary Mojo Score for Viyash Scientific currently stands at 71.0, reflecting a positive outlook on the company’s fundamentals and market positioning. This score underpins the recent upgrade in the Mojo Grade from Hold to Buy on 24 August 2026, signalling increased confidence in the stock’s potential to deliver shareholder value.

The upgrade is supported by the valuation grade change from expensive to fair, which suggests that the stock is no longer overvalued relative to its earnings and book value. This shift is critical for investors seeking to balance growth potential with reasonable entry prices in the small-cap pharmaceutical space.

Risks and Considerations

Despite the positive signals, investors should remain mindful of certain risks. The stock’s P/E ratio, while fair relative to its history, remains elevated compared to the broader market, implying that expectations for earnings growth remain high. Additionally, the company’s ROE of 7.11% indicates moderate profitability, which may limit upside if operational improvements do not materialise as anticipated.

Moreover, the recent short-term price decline and underperformance relative to the Sensex over the past week highlight potential volatility. Investors should consider these factors alongside the company’s fundamentals and valuation improvements when making investment decisions.

Conclusion: A Balanced Opportunity in a Competitive Sector

Viyash Scientific Ltd’s recent valuation grade improvement from expensive to fair, combined with a Mojo Grade upgrade to Buy, marks a significant turning point for the stock. The company’s valuation metrics now present a more attractive entry point relative to its historical levels and many of its peers, which remain expensive or very expensive.

While the stock has experienced short-term price pressure, its strong year-to-date and longer-term returns relative to the Sensex demonstrate resilience and growth potential. Operational metrics such as ROCE and ROE provide a foundation for sustainable performance, though investors should remain cautious of the elevated P/E ratio and sector volatility.

Overall, Viyash Scientific offers a compelling proposition for investors seeking exposure to the Pharmaceuticals & Biotechnology sector’s small-cap segment, balancing growth prospects with improved valuation discipline.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today